European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

Development of a novel replication-deficient mucosal rna vaccine protecting against respiratory viral disease of early childhood

Objective

The aim of the project is the development and the pre-clinical evaluation of a mucosal RNA-based virosomal vaccine against respiratory diseases of the early childhood caused by human parainfluenzavirus type 3 and respiratory syncytial virus. Antigens are encoded on a Sendai virus RNA packaged in a nucleocapsid and encapsulated into immunostimulating reconstituted virosomes. For an excellent safety standard, the nucleocapsid is completely replication-deficient by deletion of the N gene. Antigen combinations are provided by a single vaccine formulation in a modular system. The vaccine will be applied in a one step process and the administration as a nasal spray allows an easy reapplication. This makes the new formulation economic, effective, safe and highly adaptable for vaccination of humans (also of animals) against various infectious diseases.

Call for proposal

Data not available

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
EU contribution
No data
Address
Am Klopferspitz 18 A
82152 PLANEGG / KRAILLING
Germany

See on map

Total cost
No data

Participants (3)